Table 4.
Multivariate analysis of factors associated with outcomes of patients with Ph positive ALL who underwent MSDT (n = 61).
| Covariate | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | |
| Relapse | ||||||
| Disease status (CR > 1 vs. CR1)* | 5.672 | 1.455–22.117 | 0.012 | |||
| Pre-transplantation MRD (positive vs. negative) | 6.049 | 1.829–20.007 | 0.003 | 6.049 | 1.829–20.007 | 0.003 |
| Leukemia-free survival | ||||||
| Pre-transplantation MRD (positive vs. negative) | 2.797 | 1.096–7.140 | 0.031 | 2.797 | 1.096–7.140 | 0.031 |
| Overall survival | ||||||
| Pre-transplantation MRD (positive vs. negative) | 3.256 | 1.234–8.594 | 0.017 | 3.256 | 1.234–8.594 | 0.017 |
| Sex (male vs. female) | 0.430 | 0.159–1.164 | 0.097 | |||
MSDT, human leukocyte antigen-matched sibling donor transplantation; HR, hazard ratio; CI, confidence interval.
*
All variables were first included in the univariate analysis, including sex, age, donor-recipient sex-matched grafts, donor-recipient relationship, ABO matched graft, pre-transplantation MRD status, disease status and engraftments; only variables with P < 0.1 were included in the Cox proportional hazards model with time-dependent variables.